Improving Healthspan and Increasing Lifespan
Eos SENOLYTIX™ and Phoenix SENOLYTIX™ are affiliated with GEROTHERAPEUTIX, Inc.
Aging is the primary risk factor for chronic diseases, including cancer, Alzheimer’s Disease, diabetes, osteoarthritis, macular degeneration, along with many others. Gerotherapeutics aim to target aging’s underlying biological processes to extend healthspan and reduce healthcare burdens. It has been said that a successful gerotherapeutic would have a value that is too high to calculate — it instantly would become the most valuable medical intervention in history because of the number of person-years of healthy life that could be manufactured.
Eos SENOLYTIX is a longevity company using advanced technologies to develop novel peptide therapeutics targeting the fundamental mechanisms of aging and our affiliate, is pioneering innovative therapies with “best-in-class” pre-clinical Proof of Concept as the world’s first safe and effective gerotherapeutics. The Company’s lead programs, focused on their proprietary gerotherapeutic peptides, have the remarkable ability to rejuvenate naturally aged mice via two separate mechanisms, both targeting the MMP (ΔΨm), to dramatically eliminate senescent cells throughout the body in the medium to longer term, and to enhance the efficiency of mitochondrial function in those senescent cells, and possibly also in non-senescent cells, in the short term, with no apparent adverse side effects. Our peptides work via a completely novel mechanism of action, targeting the lower and declining ΔΨm found in senescent cells compared to non-senescent cells, that develops as we age. By targeting the fundamental processes driving aging and aging-related diseases, Eos SENONLYTIX has a unique opportunity to intervene in the aging process in ways that were once thought impossible, to improve healthspan and increase lifespan.
Phoenix SENOLYTIX, another of our affiliate companies, is a longevity company using advanced technologies to develop novel gene therapies targeting the fundamental mechanisms of aging. Its lead program, utilizing its proprietary purposeful cell elimination technology, ApoptiCIDe™, targets senescent cells for elimination, restoring the youthful balance of aged or “senescent” and young cells throughout the organs of the body. Its leadership team were the founders of Bellicum Pharmaceuticals, the first CAR-T cell company, in 2004. Inventors of CaspaCIDe™ at Bellicum, the most effective cell therapy safety switch validated in humans, they have now repurposed this technology, previously established as both safe and effective senolytic therapy in the p16Ink4a-ATTAC mouse model of genomic ablation of senescent cells, now as ApoptiCIDe™ to target senescent cells for non-inflammatory, apoptotic elimination. ApoptiCIDe™ is also being developed as a regulatable gene therapy platform in order ensure safety, broadening pro-healthspan gene therapy applicability beyond monogenic gene replacement.
